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 Abstract 
Background:   Deprivation, non-white ethnicity and young age are associated with late 
presentation of breast cancer. Older women are less likely to have surgery. The aim of this 
study was to identify groups likely to present with early or late breast cancer and to examine 
operation rates in a large population. 
Methods:   Registrations for 2007 were combined with Hospital Episode Statistics (HES) 
comorbidity data for England.  Early breast cancer was correlated to the Nottingham 
Prognostic Index (NPI) Excellent and Good Prognostic Groups (EPG/GPG) and tumours 
PP/DWHSUHVHQWDWLRQZDVFRUUHODWHGWRWKH3RRU3URJQRVWLF*URXS33*DQGQRW
receiving surgery.  Adjustments were made for age, deprivation, ethnicity, screen-detection 
(SD) and Charlson comorbidity score. 
5HVXOWV(3**3*WXPRXUVRUWXPRXUVPPZHUHPRUHOLNHO\LQWKH6'DQGPRUH
affluent cohorts. Those aged 0-39 or of Black/Asian ethnicity were less likely to have 
EPG/GPG tumours.   PPG tumours were less likely in women aged 60-69 and in the SD 
cohort.  
Women aged 70-79 were more likely to present with good prognosis tumours (p<0.01) but 
those over 70 were less likely to have small tumours. 
7KRVHDJHGRUZLWKD&KDUOVRQVFRUHRIZHUHOHVVOLNHO\WRUHFHLYHVXUJHU\S 
Conclusions:   Women with screen-detected breast cancer or from affluent cohorts were 
likely to have tumours of good prognosis.  Young women, deprived patients and certain 
ethnic groups present with more advanced tumours.   Older women have larger tumours but 
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Introduction   
The Second All Breast Cancer Report (SABCR), which analysed over 50,000 cases of 
breast cancer presenting in the UK in 2007, highlighted the increasing evidence that 
deprivation and older age are associated with late presentation of breast cancer1.   However, 
this study confirmed that, although older women were less likely to have small tumours and 
to be treated by surgery, the prognostic features of their breast cancers were otherwise more 
favourable 2, 3.  There is increasing concern that older women may be denied surgical 
treatment solely on the ground of age 4, but it seems likely that comorbidity may be a 
significant confounding factor 5.   Records of comorbidity available for England and the 2007 
SABCR data for England alone have therefore been further analysed to examine this 
question. 
The aim of this study was to identify those groups likely to present with early or late breast 




Data for the cohort of women in England included in the SABCR  were constructed using 
National Cancer Registration Database (NCDR), Hospital Episode Statistics (HES), Breast 
Cancer Clinical Outcome Measures (BCCOM) audit and NHS Breast Screening Programme 
and Association of Breast Surgery audit data.  The likelihood of presenting with early breast 
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Index (NPI) Excellent & Good Prognostic Groups (EPG/GPG) and b) a tumour with diameter 
of 20mm or less.  The likelihood of late detection of breast cancer was correlated to c) the 
NPI Poor Prognostic Group (PPG) and d) not having a surgical operation. 
Each of the four outcomes (as defined above) were analysed with the following factors: age 
JURXSE\GHFDGHIURP39 to 80+ years, ethnic group, deprivation quintile, comorbidity as 
assessed by the Charlson Comorbidity Index 6 and screening status; these were included as 
potential explanatory variables in the regression models. 
In order to calculate Charlson Co-morbidity Index scores, individual patients were matched 
to HES data in order to identify episodes of treatment for comorbid conditions in the 30 
months prior to and 3 months post cancer diagnosis. The scores associated with each 
comorbid 6 condition were then summed in order to provide an overall score for each patient. 
Where a patient had similar conditions recorded (e.g. liver disease and severe liver disease) 
the condition with the highest score was retained. The index cancer and all other cancer 
diagnoses were removed from the calculation so that a comorbidity score in the absence of 
cancer was derived. 
Charlson comorbidity scores were not obtained for 3,996 patients (11%) who could not be 
matched to a HES record.  The proportion of patients without a HES match varied from 8% 
in the 0-39 year age group to 10% in those aged 70-79 years and 22% in those aged 80 
years and above (Table 2). 
Statistical analysis.  A number of binary variables were generated based upon tumour 
characteristics (NPI and tumour size), and the presence/absence of surgical treatment in 
order to distinguish between Early/Not Early and Late/Not Late diagnosis. The likelihood of 
presenting with early or late presentation breast cancer was investigated using multivariate 
logistic regression models. The effect of ethnicity, age at diagnosis, surgical treatment, 
deprivation, co-morbidity and method of presentation were included as independent 
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adjusted odds ratios. The following were used as the base level for comparison: age group - 
50-59 years; deprivation quintile - most deprived (quintile 1); ethnicity - white; surgical 
treatment - surgery; screening status - symptomatic; Charlson Comorbidity Index score = 0.  
Early or Late presentation were the dependent variables throughout.  All analyses were 
conducted in Stata 11.2 (StataCorp LP, College Station, Texas USA). 
 
Results 
In 2007, 37,113 women in England presented with primary invasive breast cancer, of whom 
30,318 (82.7%) had their first surgical treatment within 6 months of their diagnosis recorded 
in the NCDR).    A further 351 women (1%) had their first surgical treatment within 6 months 
of their diagnosis recorded on HES and 135 women had their first surgery between 6 months 
and two years after their diagnosis (0.4%). 
The proportion of women who did not have surgery within 6 months recorded in the NCDR 
was 8.4% in those aged under 70 years, but this rose to 22% in those aged 70-79 years and 
59% in those aged 80 years or over (Table 1).  In women aged under 80 years, a Charlson 
Comorbidity Index (CCI) score could be derived for 91% of women, but in those aged 80 
years and over, a CCI score was available for only 78% of cases.  In women aged under 70 
years, a CCI score of greater than 2 was recorded for 2.1% of cases, rising to 5.9% in those 
aged 70-79 years and 8.7% in those aged 80 years and over. For women aged 0-69 years, 
the proportion of cases recorded with a CCI score of 0 was 86% (decreasing from 94% (0-39 
years) to 82% (60-69 years). Even in those women aged 70 years or over, 72% had no 
recorded comorbidity (CCI score = 0) (Table 2). 
The following groups were  more likely to have a good prognosis EPG/GPG breast cancer 
(p<0.02): women whose breast cancer was screen-detected rather than symptomatic; 
women from the average and most affluent cohorts (quintiles 3 & 5); women aged 40-49 
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aged 0-39 years were  less likely to have an EPG/GPG breast cancer (p,0.02): (Figure 1 and 
Table 3). 
 
The following groups were more likely to have a small breast cancer <20mm in diameter: 
women whose breast cancer was screen-detected; women from the average, the more and 
most affluent cohorts (quintiles 3 - 5); women aged 40-49 years and 60-69 years.  Women of 
BAE, women aged 70-79 years and 80 years or over were statistically significantly less likely 
to have a breast cancer <20mm in diameter (p<0.03) (Figure 2 and Table 4). 
 
Women of BAE and of Chinese or other ethnicity were more likely to have a poor prognosis 
PPG breast cancer (p=0.02):  Women aged 60-69 years and women with screen-detected 
breast cancers were less likely to have a poor prognosis PPG breast cancer (p=0.02) 
(Figure 3 and Table 5).   Women with screen-detected breast cancers were significantly less 
likely not to have an operation (p<0.001).  Women aged 70-79 years and 80 years or over, 
and women with a CCI score of 2 or more, were more likely not to have an operation 
(p=0.01). However, the availability of HES data is dependent on a hospital admission and it 
is probable that  those women who did not have surgery will have had a higher level of 
comorbidity.  (Figures 4 & 5 and Table 6).  
 
Discussion 
This study has shown in a large population that the prognostic indicators for breast cancer at 
presentation and the primary treatment vary with socio-economic status, ethnicity, screen 
detection, comorbidity and age.  There is a wealth of evidence in the literature that older 
women with breast cancer receive less aggressive treatment for operable breast cancer  in 
terms of surgery (4), radiotherapy 7 and chemotherapy 8 .    The question that remains 
unanswered is whether they are disadvantaged mainly on the basis of their age or whether 
individual circumstances including patient choice indicate that conservative management 


































































ςαριατιον ιν Προγνοσισ  ς28 17 10 2013.δοχξ  7 
origins 9, 10 may be particularly at risk of suboptimal treatment outcomes and there is 
increasing evidence that comorbidity has to be considered in the multidisciplinary 
management of patients 11. 
The First All Breast Cancer Report on symptomatic and screen-detected breast cancers in 
the UK presenting in 2006, showed that in England those known to be of black ethnicity were 
more likely to present with larger, poor prognosis tumours and at an earlier age than the 
white population 10.  The Second All Breast Cancer Report on symptomatic and screen-
detected breast cancers in the UK presenting in 2007, confirmed that screen-detected 
cancers were smaller and of a better prognosis and, as with most studies, that although 
tumours in older women were larger, they were biologically less active 1-3, 12, 13.  This  is 
consistent with the findings in the 70-79 year old age group in the present study,   Social 
deprivation was associated with more advanced tumours and worse survival 1.   
 
The present study reanalysed the 2007 data collected for England where comorbidity data 
are available, and this additionally shows that women with a CCI score of 2 or more have a 
significantly increased likelihood of not having surgery for their newly diagnosed breast 
cancer.  Older patients are shown to have a higher prevalence of significant morbidity (Table 
2) but, of those aged 70 years or over, 72% had no recorded morbidity (CCI score = 0) and, 
of those aged over 80 years, only 9% had a CCI score of two or more.  Jacobs et al have 
shown that comorbidity rapidly increases from age 78 years so that at age 85 years the rate 
is triple that of those aged 70 years 14. Only 41% of the 80+ year age group had surgical 
treatment and, although it is likely that comorbidity is only a contributory factor for the very 
low rate of surgical treatment for operable breast cancer, most of those who did not have 
surgery will not have a HES record of comorbidity.  It is also evident that the level of 
comorbidity recorded on HES is significantly under-recorded 15, 16.   
 
 Nevertheless, the currently available information shows that this is a significant factor in the 
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commonly reported in association with comorbidity and patient preference 17, and it would 
seem that patient preference and perhaps clinical preference for non-operative primary 
treatment in the elderly may be the prime cause of what might appear to be suboptimal care.   
 
Most published studies on comorbidity show that patients who receive less aggressive 
treatment fare worse 11, 18.  Age and comorbidity are closely inter-related and the latter 
becomes more severe with increasing age but in patients aged over 80 years, treatment is 
less aggressive and age is the stronger determinant 19.   Surgical treatment  in  the age 
group 70-79 years is rather less than in those aged under 70 years (78% vs 92% in the 
present study), but the picture for patients aged 80 years or over is very different, with much 
lower rates for both surgery 4 and adjuvant therapy 20.   Racial differences in comorbidity, 
apart from deprivation are mostly related to an increased prevalence of hypertension  and 
diabetes in Black  populations 21 but cardiovascular disease and mental illness are the most 
important factors in European populations 18.   In the present study the more affluent were 
more likely to present with good prognosis breast cancer and those of Black or Asian 
ethnicity were more likely to have tumours which carry a poor outlook.   The finding of poor 
outcomes in the most deprived in the population and some ethnic groups is well documented 
in the literature 1, 9.  Patients aged 0-39 years were less likely to present with favourable 
tumours which is not unexpected, but conversely, those aged 40-49 years fared better.  
Women in the age group 60-69 years were more likely to have good prognosis tumours than 
those aged 50-59 years, which might be explained by an increased proportion of screen-
detected tumours detected in the incident (subsequent) screening round versus the 
prevalent first screening round. 
Several studies have shown that intercurrent disease outpaces breast cancer as the leading 
cause of death in the elderly 22-24.   Comorbidity makes a greater difference to survival in 
patients with low risk breast cancer 17, 22 and with increasing CCI score the risk of dying of 
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the ATAC trial at 10 years showed that the risk of recurrence increased with age, and the 
risk of death without recurrence increased with age and comorbidity score 25. 
There are several randomised trials which compare surgery with or without tamoxifen versus 
conservative hormone treatment alone for operable breast cancer in the elderly, but only one 
trial has shown a modest overall survival advantage for the surgical removal of the tumour 26.  
Nevertheless, a Cochrane Review concluded that surgery for the elderly with ER positive 
early breast cancer gives better local control, and that primary endocrine therapy (PET) 
should be reserved for patients with significant comorbid disease or who refuse surgery 27.   
When PET is used in the appropriate setting the outcome is satisfactory, and although Hille 
et al found that, of those patients initially considered unfit for or who declined surgery, 39% 
eventually had an operation 28, that was not the finding in the present study. 
With increasing age, patients with operable breast cancer who are offered an informed 
choice between primary endocrine therapy (PET) and surgery, up to half may opt to avoid or 
delay operative treatment 29.    A cancer-specific geriatric assessment  of functional capacity 
predicts overall survival and may be useful in guiding decision making 30, but to involve 
patients in the decision making is important 31 )URPWKHSDWLHQW¶VSHUVSHFWLYHLIRIIHUHGD
choice between an operation and perhaps trying the effect of hormone treatment first, the 
latter option may be very persuasive, even if the possible downsides of avoiding surgery 
KDYHEHHQVSHOWRXW)URPWKHFOLQLFLDQ¶VYLHZSRLQW6WRWWHUKDVIRXQGWKDWWKHSDWLHQW¶VIUDLOW\
may be overestimated and their life expectancy underestimated.  Furthermore the difficulty 
of communicating the options is greater than in a younger person 31.  Clearly comorbidity is a 
factor which may weigh against surgery in the elderly, but to what extent this consideration is 
responsible for the best option to be declined is uncertain. 
Patients at the extremes of age, deprived patients and certain ethnic groups may present 
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That elderly patients present with larger tumours may be related to lack of screening in this 
age group but this may influence against surgery for otherwise good prognosis tumours. 
However, the failure to operate for early breast cancer in the elderly may be related to 
comorbidity as well as patient choice. 
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Φιγυρε χαπτιονσ. 
Φιγυρε 1    Λικελιηοοδ οφ πρεσεντινγ ωιτη α γοοδ προγνοσισ βρεαστ χανχερ (ΕΠΓ/ΓΠΓ) 
&ŝŐƵƌĞ ?>ŝŬĞůŝŚŽŽĚŽĨƉƌĞƐĞŶƚŝŶŐǁŝƚŚĂƐŵĂůůďƌĞĂƐƚĐĂŶĐĞƌA? ? ?ŵŵ 
Φιγυρε 3   Λικελιηοοδ οφ πρεσεντινγ ωιτη α ποορ προγνοσισ βρεαστ χανχερ (ΠΠΓ)  
 Φιγυρε 4   Λικελιηοοδ οφ νοτ ηαϖινγ α συργιχαλ οπερατιον  
Φιγυρε 5   ςαριατιον ωιτη αγε ανδ χοmορβιδιτψ ιν τηε νυmβερ οφ ωοmεν ρεχειϖινγ συργερψ φορ ινϖασιϖε 
βρεαστ χανχερ 
 
Λεγενδ οφ Ταβλεσ  
Ταβλε 1   ςαριατιον ιν Συργιχαλ Τρεατmεντ ωιτη αγε ατ διαγνοσισ 
Ταβλε 2   ςαριατιον ιν Χηαρλσον Χοmορβιδιτψ Ινδεξ Σχορε ωιτη αγε γρουπ 
Ταβλε 3   Λικελιηοοδ οφ πρεσεντινγ ωιτη α γοοδ προγνοσισ βρεαστ χανχερ (ΕΠΓ/ΓΠΓ) 
Ταβλε 4   Λικελιηοοδ οφ πƌĞƐĞŶƚŝŶŐǁŝƚŚĂƐŵĂůůďƌĞĂƐƚĐĂŶĐĞƌA? ? ?ŵŵ 
Ταβλε 5   Λικελιηοοδ οφ πρεσεντινγ ωιτη α ποορ προγνοσισ βρεαστ χανχερ (ΠΠΓ)  





















































































Age Number Proportion Number Proportion Total
0-39 1,549 90% 175 10% 1,724
40-49 4,986 91% 508 9% 5,494
50-59 7,637 93% 602 7% 8,239
60-69 8,754 91% 831 9% 9,585
70-79 5,108 78% 1,436 22% 6,544
80+ 2,284 41% 3,243 59% 5,527
Total 30,318 82% 6,795 18% 37,113
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 Charlson score = 3
 Other/Chinese
 Charlson score = 2
 Charlson score = 1
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Aged 0-39 -4.49 0.00
Aged 40-49 2.30 0.02
Aged 50-59
Aged 60-69 3.44 0.00
Aged 70-79 3.76 0.00
Aged 80+ 1.27 0.20
Surgical treatment
Surgery
No surgery -1.44 0.15
Deprivation
Most deprived
More deprived 1.04 0.30
Average deprivation 3.13 0.00
More affluent 1.77 0.08
Most affluent 2.48 0.01
Comorbidity
Charlson score = 0
Charlson score = 1 0.34 0.73
Charlson score = 2 -0.03 0.98
Charlson score = 3 -1.39 0.16
Charlson score  4 0.92 0.36
Screening status
Symptomatic
Screen detected 40.42 0.00
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 Charlson score = 4=>
 Charlson score = 3
 Charlson score = 1
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Aged 0-39 1.41 0.16
Aged 40-49 2.44 0.01
Aged 50-59
Aged 60-69 2.36 0.02
Aged 70-79 -3.65 0.00
Aged 80+ -6.69 0.00
Surgical treatment
Surgery
No surgery -1.67 0.09
Deprivation
Most deprived
More deprived 1.77 0.08
Average deprivation 2.41 0.02
More affluent 3.19 0.00
Most affluent 2.54 0.01
Comorbidity
Charlson score = 0
Charlson score = 1 -0.56 0.57
Charlson score = 2 -0.42 0.68
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 Charlson score = 2
 More deprived
 No surgery
 Charlson score = 4=>
 Charlson score = 1
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Aged 0-39 1.50 0.13
Aged 40-49 -1.40 0.16
Aged 50-59
Aged 60-69 -2.38 0.02
Aged 70-79 -0.57 0.57
Aged 80+ -1.25 0.21
Surgical treatment
Surgery
No surgery 0.93 0.35
Deprivation
Most deprived
More deprived 0.85 0.39
Average deprivation -0.58 0.56
More affluent -0.21 0.83
Most affluent -0.26 0.79
Comorbidity
Charlson score = 0
Charlson score = 1 1.22 0.22
Charlson score = 2 0.09 0.93
Charlson score = 3 1.43 0.15
Charlson score  4 1.04 0.30
Screening status
Symptomatic
Screen detected -29.10 0.00
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 Charlson score = 1
 Charlson score = 3
 Charlson score = 4=>
 Aged 70-79
 Charlson score = 2
 Aged 80+
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Aged 0-39 -1.06 0.29
Aged 40-49 1.13 0.26
Aged 50-59
Aged 60-69 0.52 0.60
Aged 70-79 2.77 0.01






More deprived -0.66 0.51
Average deprivation -0.11 0.91
More affluent 0.00 1.00
Most affluent 0.15 0.88
Comorbidity
Charlson score = 0
Charlson score = 1 1.16 0.25
Charlson score = 2 3.54 0.00
Charlson score = 3 2.08 0.04
Charlson score  4 2.35 0.02
Screening status
Symptomatic
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Age group at diagnosis
CCI>2 No surgery Surgery















Age Number Proportion Number Proportion Total
0-39 1,549 90% 175 10% 1,724
40-49 4,986 91% 508 9% 5,494
50-59 7,637 93% 602 7% 8,239
60-69 8,754 91% 831 9% 9,585
70-79 5,108 78% 1,436 22% 6,544
80+ 2,284 41% 3,243 59% 5,527
Total 30,318 82% 6,795 18% 37,113
Received surgery Did not receive surgery
Surgery
Table(s)
Ταβλεσ 1−6.δοχξ  2 
















Aged 0-39 -4.49 0.00
Aged 40-49 2.30 0.02
Aged 50-59
Aged 60-69 3.44 0.00
Aged 70-79 3.76 0.00
Aged 80+ 1.27 0.20
Surgical treatment
Surgery
No surgery -1.44 0.15
Deprivation
Most deprived
More deprived 1.04 0.30
Average deprivation 3.13 0.00
More affluent 1.77 0.08
Most affluent 2.48 0.01
Comorbidity
Charlson score = 0
Charlson score = 1 0.34 0.73
Charlson score = 2 -0.03 0.98
Charlson score = 3 -1.39 0.16
Charlson score  4 0.92 0.36
Screening status
Symptomatic
Screen detected 40.42 0.00
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Aged 0-39 1.41 0.16
Aged 40-49 2.44 0.01
Aged 50-59
Aged 60-69 2.36 0.02
Aged 70-79 -3.65 0.00
Aged 80+ -6.69 0.00
Surgical treatment
Surgery
No surgery -1.67 0.09
Deprivation
Most deprived
More deprived 1.77 0.08
Average deprivation 2.41 0.02
More affluent 3.19 0.00
Most affluent 2.54 0.01
Comorbidity
Charlson score = 0
Charlson score = 1 -0.56 0.57
Charlson score = 2 -0.42 0.68















































Aged 0-39 1.50 0.13
Aged 40-49 -1.40 0.16
Aged 50-59
Aged 60-69 -2.38 0.02
Aged 70-79 -0.57 0.57
Aged 80+ -1.25 0.21
Surgical treatment
Surgery
No surgery 0.93 0.35
Deprivation
Most deprived
More deprived 0.85 0.39
Average deprivation -0.58 0.56
More affluent -0.21 0.83
Most affluent -0.26 0.79
Comorbidity
Charlson score = 0
Charlson score = 1 1.22 0.22
Charlson score = 2 0.09 0.93
Charlson score = 3 1.43 0.15
Charlson score  4 1.04 0.30
Screening status
Symptomatic
Screen detected -29.10 0.00
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Aged 0-39 -1.06 0.29
Aged 40-49 1.13 0.26
Aged 50-59
Aged 60-69 0.52 0.60
Aged 70-79 2.77 0.01






More deprived -0.66 0.51
Average deprivation -0.11 0.91
More affluent 0.00 1.00
Most affluent 0.15 0.88
Comorbidity
Charlson score = 0
Charlson score = 1 1.16 0.25
Charlson score = 2 3.54 0.00
Charlson score = 3 2.08 0.04
Charlson score  4 2.35 0.02
Screening status
Symptomatic
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Φιγυρε 3   Λικελιηοοδ οφ πρεσεντινγ ωιτη α ποορ προγνοσισ βρεαστ χανχερ (ΠΠΓ)  
 Φιγυρε 4   Λικελιηοοδ οφ νοτ ηαϖινγ α συργιχαλ οπερατιον  

















 Charlson score = 3
 Other/Chinese
 Charlson score = 2
 Charlson score = 1

































 Charlson score = 4=>
 Charlson score = 3
 Charlson score = 1









1 2 3 4
Odds ratio
Significant Not significant
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 Charlson score = 2
 More deprived
 No surgery
 Charlson score = 4=>
 Charlson score = 1





1 2 3 4
Odds ratio
Significant Not significant
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 Charlson score = 1
 Charlson score = 3
 Charlson score = 4=>
 Aged 70-79
 Charlson score = 2
 Aged 80+
5 10 15 20 25
Odds ratio
Significant Not significant

































Age group at diagnosis
CCI>2 No surgery Surgery




Χονφλιχτ οφ ιντερεστ στατεmεντ. 
WŽƉƵůĂƚŝŽŶďĂƐĞĚƐƚƵĚǇŽĨǀĂƌŝĂƚŝŽŶƐ ? ? 
 
Τηε αυτηορσ τηανκ τηε mεmβερσ οφ τηε ΒΧΧΟΜ Στεερινγ Γρουπ φορ τηειρ συππορτ ανδ φορ τηε δατα 
προϖιδεδ ανδ θυαλιτψ ασσυρεδ βψ τηε Ενγλιση Χανχερ Ρεγιστρατιον Σερϖιχε,  ανδ τηε ΝΗΣ Βρεαστ 
Σχρεενινγ Προγραmmε ανδ τηε Ασσοχιατιον οφ Βρεαστ Συργερψ αυδιτ. 
Τηε ΒΧΧΟΜ Προϕεχτ ωασ ινιτιαλλψ φυνδεδ βψ Βρεακτηρουγη Βρεαστ Χανχερ ανδ ισ νοω φυνδεδ βψ τηε 
Νατιοναλ Χανχερ Ιντελλιγενχε Νετωορκ. 
Χονφλιχτ οφ ιντερεστ. 
Τηε αυτηορσ δεχλαρε νο χονφλιχτ οφ ιντερεστ 
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